Rescue therapy in septic shock – is terlipressin the last frontier 英文参考文献.docVIP

Available online /content/10/2/131 Commentary Rescue therapy in septic shock – is terlipressin the last frontier? Marc Leone and Claude Martin Intensive Care Unit and Trauma Center, Nord University Hospital, Marseilles School of Medicine, Marseilles, France Corresponding author: Claude Martin, claude.martin@mail.ap-hm.fr Published: 21 March 2006 Critical Care 2006, 10:131 (doi:10.1186/cc4863) This article is online at /content/10/2/131 ? 2006 BioMed Central Ltd See related research by Rodriguez-Nunez et al. in issue 10.1 [/content/10/1/R20] Abstract dispense lysine vasopressin, or terlipressin (Glypressine ?; Ferring Company, Berlin, Germany), which is the form of vasopressin that is present in pig. Use of terlipressin, an analogue of vasopressin, can be considered in septic shock patients with intractable hypotension and high cardiac output in whom fluid resuscitation and high-dose conventional catecholamines have failed. The effects of this agent on organ function are poorly evaluated in humans. The limited number of patients evaluated precludes any analysis of adverse outcomes and prognosis. The first clinical trial evaluating the efficacy of terlipressin in septic shock was performed in a small case series of eight patients [2]. Terlipressin was administered as a single bolus of 1 mg (the dosage used in gastroenterological indications) in patients with septic shock refractory to catecholamine/ In the previous issue of Critical Care, Rodriguez-Nunez and coworkers [1] report their experience with terlipressin in 16 children with refractory septic shock. Over the past few years there has been much interest in the use of terlipressin in such settings, both in adults [2-6] and children [7-10]. hydrocortisone/methylene blue. A significant improvement in blood pressure was achieved in these patients during the first 5 hours. Cardiac output was